The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.
Mayer Fishman, MD, PhD
Advertisement
Articles by Mayer Fishman, MD, PhD
Mayer Fishman, MD, PhD, medical oncologist, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, professor, Department of Oncologic Sciences and of Internal Medicine, University of South Florida Morsani College of Medicine, discusses the available agents to treat patients with renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Fishman Discusses Available Agents to Treat Patients With RCCPublished: August 16th 2016 | Updated:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsPublished: July 19th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5